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TO THE EDITOR
We thank Dr Nijsten (2012) for his
positive comments concerning the ubi-
quity and impressive track record of the
Dermatology Life Quality Index (DLQI),
and for agreeing that it is reliable, valid,
and easy to use. In the Editorial,
attention is drawn to theoretical limita-
tions of the measure and at the same
time Skindex is promoted.
It is implied that the questions of the
DLQI were ‘‘yselected by the re-
searchers based on existing tools, with-
out input from patients’’. In fact, the
questions were derived entirely from
the experience of 120 adult patients
with a variety of skin diseases (Finlay
and Khan, 1994), as acknowledged
previously (Nijsten et al., 2006). This
aspect of the DLQI has been a major
strength of this instrument in that the
questions have a high face validity with
patients, reflecting the reality of the
patient experience in living with skin
disease. In contrast to the conclusions
reached by Twiss et al. (2012), in-depth
interviews with patients with psoriasis
revealed that patients considered that
all of the important ways in which
their lives were affected by psoriasis
were covered by the DLQI questions
(Safikhani et al., 2011). Scrutiny of the
DLQI in its use in many hundreds of
research studies has unfolded new
properties or reconfirmed its original
concepts (Basra et al., 2008).
Nijsten states that the Item Response
Theory (IRT) methodology is considered
the ‘‘gold standard’’ in the develop-
ment of Health-Related Quality of Life
(HRQoL) instruments, and we agree
that it is important to use the highest
quality psychometric techniques such
as the IRT. However, this does not
mean that the Classical Test Theory
(CTT) is wrong; it is still being used for
the development and validation of new
HRQoL instruments (Evers et al., 2008),
and the person and item statistics
derived from these two measurement
models are comparable (Xitao, 1998;
Lin, 2008).
CTT has the advantage that data
are not fitted to a predetermined
mathematical model, and thus assump-
tions do not need to be met before
developing this framework, and a dis-
advantage of Rasch analysis is the need
for larger sample sizes. Skindex-29 was
created using the CTT and does not fit
the Rasch model (though Skindex-17
does); thus, it is not possible to say from
a methodological viewpoint whether
it is worse or better than the DLQI.
Although Nijsten quotes evidence
against the unidimensionality of the
DLQI (Nijsten et al., 2006), there are
other reports supporting its unidimen-
sional nature and hence the use of a
summary score (Mork et al., 2002;
Lennox and Leahy, 2004; Mazzotti
et al., 2005; Takahashi et al., 2006;
He et al., 2011).
Nijsten has suggested a ‘‘genera-
tion’’ classification of HRQoL tools,
but not every quality-of-life (QoL) tool
fits neatly into this labeling scheme.
Although by being the first dermatol-
ogy-specific tool the DLQI is by defini-
tion ‘‘first generation’’, its questions
were entirely based on the views of
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patients, apparently not a ‘‘first-genera-
tion’’ characteristic.
One aspect of the development of
the DLQI, not directly addressed in the
Editorial, is that this has been a
successful example of translational re-
search. A concept developed in a
research setting has moved into daily
clinical practice. In the UK, where it is
a requirement that the DLQI be used to
support decisions concerning biologics
in psoriasis, clinicians are familiar with
the measure and use it in other clinical
settings to inform the consultation and
to support decisions. The original stated
aim (Finlay and Khan, 1994) was for the
DLQI to be useful in routine daily
clinical practice.
As implied by Nijsten (2012), clin-
ical practice and physician habits are
notoriously difficult to influence. There
is often a lag of many years after the
introduction of new treatments or ideas
before clinicians’ behavior changes.
After two decades, we are finally
beginning to see an awareness of the
importance of QoL issues and of the
value of their measurement in clinical
dermatology practice. To gain accep-
tance of new concepts or new ways of
thinking, messages have to be very
simple and techniques have to be very
easy to use. The DLQI was deliberately
designed to be simple to use and to
score. Moreover, it has a very simple
method of score interpretation
(410¼ very severe impact; Hongbo
et al., 2005).
An equally important aspect in the
process of promoting a shift in thinking
among clinicians is the need for con-
sistency in the methodology. The DLQI
in use today is exactly the same as that
first published in 1994 (Finlay and
Khan, 1994). Although this may be a
weakness (Nijsten, 2012), it has also
been essential in minimizing confusion
in the minds of clinicians and in
facilitating that shift from publication
to actual use in the clinic. Although
improving the validity and utility of
Skindex, the availability of subsequent
versions (-61, -29, -17, -16) may have
left clinicians confused about which is
the best version to use; indeed, the
Editorial states that two of these ver-
sions are the preferred instrument.
Nijsten raises concerns about the
theoretical limitations of the DLQI as
‘‘the continued use of this instrument
may have far-reaching clinical and
financial consequences.’’ We are not
aware of any evidence to suggest that
the continued use of the DLQI in policy
and treatment decisions has been
to the detriment of dermatological
patients. In fact, the opposite has been
the reality.
We agree that all techniques in
medicine should be critically reviewed,
and that it is important that improved
techniques be developed. The funda-
mental purpose of our research has
been to enhance the awareness of QoL
issues in daily clinical practice. This
message has still so far only reached
a small fraction of dermatologists
worldwide: we wish Dr Nijsten and
colleagues success in their continuing
valuable contributions toward this
aim. The DLQI and Skindex have
different strengths, and both resear-
chers and clinicians benefit from being
able to choose which best meets their
needs.
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